Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
93
datasets available to search
ShareScore release 0.9.0
Dataset results
93 results for “prostate specific antigen”
Prostate specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria
<p><strong>Background</strong></p> <p>This study aims to estimate the prostate specific antigen density(PSAD) cut off level for detecting prostate cancer( CAP) in Nigerian men with “grey zone PSA’’(4-10ng/ml) and normal digital rectal examination findings . We addressed this research question: Is the international PSAD cut off of 0.15 ideal for detecting CAP in our symptomatic patients with “grey zone PSA’’?</p> <p><strong> Methods</strong></p> <p>Aim: To estimate the prostate specific antigen density(PSAD) cut off level for detecting prostate cancer( CAP) in Nigerian men with “grey zone PSA’’(4-10ng/ml) and normal digital rectal examination findings .</p> <p>Design: prospective</p> <p>Setting: A tertiary medical center in Enugu Nigeria</p> <p> Participants: Two hundred and fifty four men with either benign prostatic hyperplasia (BPH) or prostate cancer (CAP) were recruited. </p> <p> Intervention: Patients with PSA above 4ng/ml or abnormal digital rectal examination or hypoecoic lesion in the prostate were biopsied.</p> <p>Outcome measures: PSAD and histology report of BPH or CAP</p> <p><strong>Results</strong></p> <p>Ninety seven patients had cancer of the prostate (CAP) while 157 has benign prostatic hyperplasia (BPH). Seventy two patients had their serum PSA value within the range of 4.0 and 10ng/ml . PSAD cut off level to detect CAP was 0.04(sensitivity 95.88 %; specificity 28.7 %).</p> <p> </p> <p><strong>CONCLUSION</strong> </p> <p>The PSAD cut off level generated for Nigerian men in this study is 0.04 which is relatively different from international consensus. This PSAD cut off level has a positive correlation with histology and could detect patients with CAP who have “grey zone PSA’’.</p>
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
ClinicalTrials.gov study NCT03042312. IPD Sharing: NO. Countries: 1. Publications: 1.
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
ClinicalTrials.gov study NCT00090363. IPD Sharing: Not stated. Countries: 14. Publications: 1.
Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
ClinicalTrials.gov study NCT01496157. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
ClinicalTrials.gov study NCT01678313. IPD Sharing: Not stated. Countries: 1. Publications: 13.
The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
ClinicalTrials.gov study NCT04936334. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
ClinicalTrials.gov study NCT03995888. IPD Sharing: NO. Countries: 1. Publications: 1.
89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
ClinicalTrials.gov study NCT02410577. IPD Sharing: Not stated. Countries: 1. Publications: 1.
High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer
ClinicalTrials.gov study NCT03327675. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen
ClinicalTrials.gov study NCT05512754. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local The
ClinicalTrials.gov study NCT05794906. IPD Sharing: NO. Countries: 23. Publications: 1.
Prospective Evaluation of 68-Ga-prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomograph (PET) and Early Prostatic Specific Antigen (PSA) Kinetics During Salvage Radiotherapy for Personal
ClinicalTrials.gov study NCT02699424. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
ClinicalTrials.gov study NCT01046916. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Adequacy of Prostate-Specific Antigen (PSA) Requests
ClinicalTrials.gov study NCT03968692. IPD Sharing: NO. Countries: 1. Publications: 1.
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
ClinicalTrials.gov study NCT06690970. IPD Sharing: NO. Countries: 1. Publications: 1.
Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy
ClinicalTrials.gov study NCT05902247. IPD Sharing: NO. Countries: 1. Publications: 1.
Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resi
ClinicalTrials.gov study NCT06809426. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer
ClinicalTrials.gov study NCT00596895. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Application Value of Prostate Specific Membrane Antigen PET/CT in Biopsy Free of PSA Grey Area Prostate Cancer
ClinicalTrials.gov study NCT05958004. IPD Sharing: Not stated. Countries: 1. Publications: 1.
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
ClinicalTrials.gov study NCT01681433. IPD Sharing: NO. Countries: 2. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.